Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HALONASDAQ:LGNDNASDAQ:MDGLNASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHALOHalozyme Therapeutics$70.05+18.0%$61.10$40.87▼$73.17$8.65B1.261.48 million shs9.68 million shsLGNDLigand Pharmaceuticals$105.62+2.2%$107.34$72.95▼$129.90$2.04B0.87119,366 shs146,571 shsMDGLMadrigal Pharmaceuticals$298.83+1.3%$323.84$200.08▼$377.46$6.63B-0.91388,555 shs359,721 shsRGENRepligen$126.88-2.7%$136.86$102.97▼$182.52$7.12B1.21723,240 shs1.38 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHALOHalozyme Therapeutics-2.05%-2.37%-0.65%+3.04%+45.33%LGNDLigand Pharmaceuticals-2.85%-7.24%+3.77%-11.93%+41.86%MDGLMadrigal Pharmaceuticals-3.67%-13.40%-6.13%-13.19%+25.28%RGENRepligen-7.47%-6.48%+16.49%-19.47%-22.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHALOHalozyme Therapeutics4.2029 of 5 stars1.31.00.04.43.42.54.4LGNDLigand Pharmaceuticals4.3602 of 5 stars3.50.00.04.43.82.51.9MDGLMadrigal Pharmaceuticals4.5739 of 5 stars4.50.00.04.63.34.20.6RGENRepligen4.8415 of 5 stars4.33.00.04.52.53.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHALOHalozyme Therapeutics 2.60Moderate Buy$63.78-8.95% DownsideLGNDLigand Pharmaceuticals 3.00Buy$146.4338.64% UpsideMDGLMadrigal Pharmaceuticals 2.90Moderate Buy$416.3339.32% UpsideRGENRepligen 2.64Moderate Buy$173.2536.55% UpsideCurrent Analyst Ratings BreakdownLatest LGND, RGEN, HALO, and MDGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025HALOHalozyme TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$60.00 ➝ $65.005/5/2025RGENRepligenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.00 ➝ $180.005/2/2025MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$441.00 ➝ $458.005/2/2025MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$422.00 ➝ $460.005/2/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$394.00 ➝ $420.004/30/2025RGENRepligenRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$202.00 ➝ $189.004/29/2025RGENRepligenJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$200.00 ➝ $190.004/29/2025RGENRepligenWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$160.004/25/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.004/24/2025MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$443.00 ➝ $443.004/21/2025HALOHalozyme TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$55.00 ➝ $58.00(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHALOHalozyme Therapeutics$1.02B8.52$5.67 per share12.35$2.95 per share23.75LGNDLigand Pharmaceuticals$167.13M12.18$4.33 per share24.39$40.39 per share2.62MDGLMadrigal Pharmaceuticals$317.38M20.91N/AN/A$20.53 per share14.56RGENRepligen$650.43M10.95$2.37 per share53.61$35.19 per share3.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHALOHalozyme Therapeutics$281.59M$3.4320.4211.260.4243.74%157.78%25.34%N/ALGNDLigand Pharmaceuticals$52.15M-$0.1642.0828.47N/A29.68%4.95%4.39%5/8/2025 (Estimated)MDGLMadrigal Pharmaceuticals-$373.63M-$18.05N/AN/AN/AN/A-71.78%-53.25%N/ARGENRepligen$35.60M-$0.45N/A53.764.54-4.64%4.21%2.94%N/ALatest LGND, RGEN, HALO, and MDGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23N/AN/AN/A$37.84 millionN/A5/6/2025Q1 2025HALOHalozyme Therapeutics$0.98$1.11+$0.13$0.93$231.21 million$264.86 million5/1/2025Q1 2025MDGLMadrigal Pharmaceuticals-$3.62-$3.32+$0.30-$3.32$112.79 million$137.25 million4/29/2025Q1 2025RGENRepligen$0.35$0.39+$0.04$0.10$163.65 million$169.17 million2/26/2025Q4 2024MDGLMadrigal Pharmaceuticals-$4.32-$2.71+$1.61-$2.71$97.81 million$103.32 million2/20/2025Q4 2024RGENRepligen$0.41$0.44+$0.03-$0.60$167.58 million$167.55 million2/18/2025Q4 2024HALOHalozyme Therapeutics$1.17$1.19+$0.02$1.06$285.74 million$298.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHALOHalozyme Therapeutics4.147.809.15LGNDLigand PharmaceuticalsN/A12.4911.81MDGLMadrigal Pharmaceuticals0.155.985.93RGENRepligen0.2610.448.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHALOHalozyme Therapeutics97.79%LGNDLigand Pharmaceuticals91.28%MDGLMadrigal Pharmaceuticals98.50%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipHALOHalozyme Therapeutics2.90%LGNDLigand Pharmaceuticals5.90%MDGLMadrigal Pharmaceuticals22.80%RGENRepligen1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHALOHalozyme Therapeutics390123.53 million120.20 millionOptionableLGNDLigand Pharmaceuticals8019.28 million17.78 millionOptionableMDGLMadrigal Pharmaceuticals9022.20 million16.84 millionOptionableRGENRepligen2,02056.15 million55.36 millionOptionableLGND, RGEN, HALO, and MDGL HeadlinesRecent News About These CompaniesRepligen's (RGEN) "Buy" Rating Reaffirmed at HC WainwrightMay 7 at 8:15 AM | marketbeat.comRepligen Corporation to Present at Upcoming May Investor ConferencesMay 7 at 7:30 AM | globenewswire.comBaird Financial Group Inc. Cuts Stake in Repligen Co. (NASDAQ:RGEN)May 7 at 6:14 AM | marketbeat.comBamco Inc. NY Lowers Position in Repligen Co. (NASDAQ:RGEN)May 7 at 5:58 AM | marketbeat.comAlyeska Investment Group L.P. Makes New Investment in Repligen Co. (NASDAQ:RGEN)May 6 at 5:30 AM | marketbeat.comSusquehanna Fundamental Investments LLC Takes Position in Repligen Co. (NASDAQ:RGEN)May 6 at 4:21 AM | marketbeat.comRepligen's (RGEN) "Buy" Rating Reiterated at HC WainwrightMay 6 at 2:33 AM | americanbankingnews.comRepligen’s Strategic Growth and Resilience Drive Buy Rating with $180 Price TargetMay 5 at 7:03 AM | tipranks.comFY2025 EPS Estimates for Repligen Boosted by William BlairMay 4 at 8:11 AM | marketbeat.comQ2 Earnings Estimate for Repligen Issued By Leerink PartnrsMay 4 at 7:15 AM | marketbeat.comQ2 Earnings Forecast for Repligen Issued By Leerink PartnrsMay 4 at 1:19 AM | americanbankingnews.comStifel Nicolaus Reaffirms Their Buy Rating on Repligen (RGEN)May 3, 2025 | theglobeandmail.comWilliam Blair Brokers Lower Earnings Estimates for RepligenMay 3, 2025 | marketbeat.comRoyal Bank of Canada Cuts Repligen (NASDAQ:RGEN) Price Target to $189.00May 3, 2025 | americanbankingnews.comFY2025 EPS Estimates for Repligen Lifted by William BlairMay 3, 2025 | americanbankingnews.comRepligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On HealthcareMay 2, 2025 | msn.comQGEN or RGEN: Which Is the Better Value Stock Right Now?May 2, 2025 | zacks.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (ATRC), SAGE Therapeutics (SAGE) and Repligen (RGEN)May 2, 2025 | theglobeandmail.comDimensional Fund Advisors LP Raises Holdings in Repligen Co. (NASDAQ:RGEN)May 2, 2025 | marketbeat.comWilliam Blair Predicts Repligen's Q2 Earnings (NASDAQ:RGEN)May 2, 2025 | americanbankingnews.comRepligen (NASDAQ:RGEN) Upgraded to "Outperform" at Wolfe ResearchMay 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatRetail Data Shows Urgency in Auto Parts: These 3 Stocks Could WinBy Gabriel Osorio-Mazilli | April 22, 2025View Retail Data Shows Urgency in Auto Parts: These 3 Stocks Could WinLGND, RGEN, HALO, and MDGL Company DescriptionsHalozyme Therapeutics NASDAQ:HALO$70.05 +10.67 (+17.97%) Closing price 03:59 PM EasternExtended Trading$70.44 +0.39 (+0.56%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Ligand Pharmaceuticals NASDAQ:LGND$105.62 +2.30 (+2.23%) Closing price 04:00 PM EasternExtended Trading$105.71 +0.09 (+0.09%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Madrigal Pharmaceuticals NASDAQ:MDGL$298.83 +3.70 (+1.25%) Closing price 04:00 PM EasternExtended Trading$298.84 +0.01 (+0.00%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Repligen NASDAQ:RGEN$126.88 -3.52 (-2.70%) Closing price 04:00 PM EasternExtended Trading$126.89 +0.01 (+0.01%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
